Pioneer Group
VC Fund
London, United Kingdom
Pioneer Group is a vertically integrated platform curating innovation-focused ecosystems that increase the chance of business success.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 9%
Last updated:
For AI agents: llms.txt
Industries Pioneer Group invests in
Stages Pioneer Group invests in
Countries Pioneer Group invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Dr Imelda Juniarsih
|
|||
4 more contacts available
Investment Focus
Industry
- Biotechnology 4 (36%)
- Medical 2 (18%)
- Therapeutics 2 (18%)
- Diabetes 1 (9%)
- Training 1 (9%)
Stage
- Seed 5 (45%)
- Venture - Series Unknown 3 (27%)
- Funding Round 2 (18%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Dr Imelda Juniarsih
Investment Associate Director
|
Investment Associate Director | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
NunaBio
|
NunaBio operates as a privately-owned specialist DNA development company. NunaBio engaged in CRO (Contract Research Organizations) and CDMO (Contract Development and Manufacturing Organisation) activities. | $8.8M / Venture - Series Unknown / Apr 30, 2026 | |
NuVision
|
NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at theUniversity of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham. | $6.5M / Venture - Series Unknown / Feb 05, 2026 | |
MNS
|
MNS is a UK-based medical technology company developing Miracus, a proprietary needle-free drug delivery platform designed to replace traditional hypodermic injections with a painless, thermally stable patch. | Seed / Nov 26, 2025 | |
ImmuONE
|
ImmuONE provides solutions for inhalation toxicology, irritation sensitization, alveolar clearance, and inflammation. If you want would contact them please contact them via phone call or email. | $777.4K / Seed / Mar 13, 2025 | |
Neobe Therapeutics
|
Neobe Therapeutics provides immunotherapies, clinical trials, research, and tumor-colonizing bacteria engineering services. | $2.3M / Seed / Feb 29, 2024 | |
|
ImmuONE
|
ImmuONE provides solutions for inhalation toxicology, irritation sensitization, alveolar clearance, and inflammation. If you want would contact them please contact them via phone call or email. | Oct 25, 2023 | |
|
ImmuONE
|
ImmuONE provides solutions for inhalation toxicology, irritation sensitization, alveolar clearance, and inflammation. If you want would contact them please contact them via phone call or email. | $2.4M / Seed / Oct 25, 2023 | |
Bastion Therapeutics
|
Bastion Therapeutics is a preclinical stage biotechnology startup that uses proprietary platform technology to boost Tregs for the immune system | $840K / Sep 12, 2023 | |
|
NunaBio
|
NunaBio operates as a privately-owned specialist DNA development company. NunaBio engaged in CRO (Contract Research Organizations) and CDMO (Contract Development and Manufacturing Organisation) activities. | $2.4M / Seed / Apr 20, 2023 | |
Kinomica
|
Kinomica is a proteomic-data science and diagnostics company specializing in cell signalling. Kinomica offers KScanTM, a powerful suite of advanced proprietary bioinformatics and phosphoproteomics analytical methods that can provide direct activity measurements of multiple endogenous kinases and comprehensive cell signalling network coverage. | $1.7M / Venture - Series Unknown / Mar 29, 2023 | |
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Pioneer Group invest in?
Pioneer Group invests primarily in Biotechnology, Medical and Therapeutics startups, most often at Seed and Venture - Series Unknown stage. Most of the 11 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Pioneer Group?
Public channels for Pioneer Group include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Pioneer Group?
The team at Pioneer Group includes Dr Imelda Juniarsih (Investment Associate Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
